Li, F., & Dong, X. (2021). Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial. Wiley.
Style de citation Chicago (17e éd.)Li, Fengtan, et Xifeng Dong. Pembrolizumab Provides Long‐term Survival Benefits in Advanced Non‐small Cell Lung Cancer: The 5‐year Outcomes of the KEYNOTE‐024 Trial. Wiley, 2021.
Style de citation MLA (8e éd.)Li, Fengtan, et Xifeng Dong. Pembrolizumab Provides Long‐term Survival Benefits in Advanced Non‐small Cell Lung Cancer: The 5‐year Outcomes of the KEYNOTE‐024 Trial. Wiley, 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.